REG - Avacta Group PLC - Avacta Announces Presentations at AACR

AvactaAnnouncement

26/03/2025 07:16

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250326:nRSZ1477Ca&default-theme=true

RNS Number : 1477C  Avacta Group PLC  26 March 2025

 

 

Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting

 

 

LONDON and PHILADELPHIA - March 26, 2025 - Avacta Therapeutics (AIM: AVCT), a
life sciences company developing next generation peptide drug conjugates (PDC)
targeting powerful anti-tumor payloads directly to the tumor, today announced
that the Company will have three presentations at the American Association for
Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL.

 

The poster presentations will feature data from the Company's proprietary
pre|CISION(®) platform and pipeline of next generation peptide drug
conjugates (PDCs), including AVA6000, a PDC consisting of doxorubicin
conjugated with a peptide moiety that is specifically cleaved by FAP in the
tumor microenvironment via a pharmacokinetics and clinical presentation, and
preclinical pharmacology highlights for AVA6103, a PDC comprised of the
pre|CISION(®) peptide linked to exatecan. The third presentation will
describe detailed analysis of the target fibroblast activation protein-alpha
(FAPα), the protease that forms the basis of the pre|CISION(®) platform.

Details for Avacta's poster presentations are below and can be found on the
AACR website (https://www.aacr.org/meeting/aacr-annual-meeting-2025/) :

 

Abstract Number and Title: #3139: The novel PDC AVA6103 is a FAP-enabled
pre|CISION(®) medicine which targets exatecan, a topoisomerase I inhibitor,
to the tumor microenvironment following FAP cleavage

·    Session Category: Experimental and Molecular Therapeutics

·    Session Title: Therapeutic Approach to Attack the Tumor
Microenvironment

·    Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT

 

Abstract Number and Title: #2699: Investigating fibroblast activation protein
alpha (FAPα) as a therapeutic target for delivery of pre|CISION(®) cancer
medicines: Expression, spatial localization and functional insights

·    Session Category: Tumor Biology

·    Session Title: Targeting the Tumor Microenvironment: A Brave New
World

·    Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT

 

Abstract Number and Title: #CT15: Comparative pharmacokinetics and tumor
activation of fibroblast activation protein (FAP)-enabled
pre|CISION(®) peptide drug conjugates

·    Session Title: First-in-Human Phase I Clinical Trials 2

·    Session Date and Time: Tuesday, April 29, 2025, 9:00 a.m. - 12:00
p.m. CT

 

 

-Ends-

For further information from Avacta, please contact:

 

 Avacta Group plc                                           https://avacta.com/ (https://avacta.com/)

 Michael Vinegrad, Group Communications

 Director

 Peel Hunt (Nomad and Broker)

 James Steel / Chris Golden                                 www.peelhunt.com (http://www.peelhunt.com/)

 Panmure Liberum (Joint Broker)                             www.panmureliberum.com (http://www.panmureliberum.com)

 Emma Earl / Will Goode / Mark Rogers

 ICR Healthcare

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert   avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Investor Contact

 Renee Leck                                                 renee@thrustsc.com (mailto:renee@thrustsc.com)

 THRUST Strategic Communications

 Media Contact

 Carly Scaduto                                              Carly@carlyscadutoconsulting.com

                                                          (https://www.globenewswire.com/Tracker?data=YG-jwixFWaHByFwlhEr4NbVmhGc9YbrV0ozbiHY-33jDG-KDtaZDvqBLS4-5RgIi5zejtwvrLPO1U6xSYlV9BnK-dIegbuZft6wwj-ugstEWYrPDSrd9NwgKYBdm1l9Ty6VSa1gsRJqxeLaMfUN-easXzPVocBafm0xbzTKFahId-T7w4WgPYGYfKdFh6MGXNNniX0b0LrpQwjqHYj_mTmjerN3nRW6pwlbWejQ6wZCns0oke-U-WA7CB-Z2CD1ObedcWrqwKYgQwTY1NxAOLXtmHTL3VJ7HZ4Z3K9ZhB_2_vgbo4aKKTppE6l1bjU2w)
 Carly Scaduto Consulting

 

 

About Avacta - https://avacta.com/ (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary warhead delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent warheads in the tumor microenvironment
while sparing normal tissues. Our innovative pipeline consists of
pre|CISION(®) peptide drug conjugates (PDC) or Affimer(®) drug conjugates
(AffDC) that leverage the tumor-specific release mechanism, providing unique
benefits over traditional antibody drug conjugates.

About the pre|CISION® Platform

The pre|CISION(®) platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumors compared
with healthy tissues. The pre|CISION(®) platform harnesses this tumor
specific protease to cleave pre|CISION(®) peptide drug conjugates and
pre|CISION(®) antibody/Affimer(®) drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and reducing
systemic exposure and toxicity, allowing dosing to be optimized to deliver the
best outcomes for patients.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFVLVAIEFIE